Beijing SL Pharmaceutical Lamivudine Receives Approval
This article was originally published in PharmAsia News
Executive Summary
Beijing SL Pharmaceutical has received a production license and new drug certification for its lamivudine capsule and lamivudine raw material for treating the hepatitis B virus. At present, TIPR Pharmaceutical's Daiding ranks top in China's lamivudine market with 57.75 percent, and GSK's Heptodin accounting for the remaining market share. According to estimates, hospitals in the country spend RMB 480 million on lamivudine and the drug will hit RMB 1 billion in revenue by 2010. Beijing SL believes that few companies have the capability to produce the drug, and supply still lags behind demand. It is thus optimistic about the potential of the product and will go into production soon. (Click here for more - Chinese Language)
You may also be interested in...
Entries Begin To Roll In For 2024 Industry Awards
Entries have now begun rolling in for the Global Generics & Biosimilars Awards, which returns to Milan this October, Free to enter and attend, the ceremony recognizes the top achievements across the generics, biosimilars and value added medicines industries.
‘I Would Love To Have All The Biologic Assets’ – Formycon’s Glombitza Sets Out Portfolio Approach
In the second part of an exclusive interview, Formycon CEO Stefan Glombitza talks to Generics Bulletin about key regulatory developments in Europe and the US, the firm’s portfolio selection strategy, and upcoming milestones on the horizon.
First Off The Blocks, Fresenius Launches US Tocilizumab Biosimilar
Fresenius Kabi has kicked off competition to Genentech’s Actemra in the US, launching its Tyenne biosimilar version of tocilizumab.